TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03468790
Drug: Ventolin
Normalized name: Ventolin
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: asthma rescue drug
Study: NCT00075777
Drug: valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg by mouth twice a day
Study: NCT04537533
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative infusion
Study: NCT04083963
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose weekly carboplatin (AUC 2) will be combined with weekly paclitaxel for 12 weeks.
Study: NCT04083963
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be given weekly along with carboplatin for 12 weeks.
Study: NCT00358215
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by subcutaneous injection
Study: NCT02609659
Drug: ombitasvir/paritaprevir/ritonavir and dasabuvir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
Study: NCT02609659
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet
Study: NCT03863977
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After the surgery, dexamethasone added to 1mg/kg of 0.5% bupivacaine in the TAP block.
Study: NCT03863977
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the surgery,1mg/kg of 0.5% bupivacaine in the TAP block.
Study: NCT01385748
Drug: Clonidine Lauriad® 50µg
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50µg muco-adhesive buccal tablet once day every day up to 8 weeks
Study: NCT01385748
Drug: Clonidine Lauriad® 100µg
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
Study: NCT02783573
Drug: Lanabecestat
Normalized name: Lanabecestat
DrugBank: Lanabecestat (DB14814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00233480
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin 10mg PO QD
Study: NCT03557983
Drug: Fenofibrate
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate is dissolved in Saline and topically spread three times per day at the irradiated areas, with a concentration of 400 μg/mL for week.
Study: NCT03557983
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline is topically spread three times per day at the irradiated areas for one week.
Study: NCT04204382
Drug: Levofloxacin Injection
Normalized name: levofloxacin Injection
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin Injection 0.5 g each time, once a day, intravenous drip.Treatment course is 7 days.
Study: NCT00721201
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of mifepristone 200mg bd for 8 weeks
Study: NCT00557557
Drug: Drug: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/m², one hour isolated hepatic perfusion prior to standard treatment.
Study: NCT01848613
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03388268
Drug: Oral Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral vancomycin 125mg 4 times per day
Study: NCT00823550
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: entecavir 0.5 mg QD
Study: NCT00823550
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lamivudine 100 mg QD
Study: NCT01863602
Drug: Lamotrigine tablets
Normalized name: Lamotrigine Tablets
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered for long-term according to the prescribing information in the locally approved label by the authorities.
Study: NCT01383993
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)
Study: NCT01383993
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h.~Notes:~If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.~Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.~(IV = Intravenous; POS = Powder for oral suspension)
Study: NCT00061620
Drug: Tezacitabine (FMdC)
Normalized name: Decitabine
DrugBank: Tezacitabine (DB06433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7.5 mg/m2 bolus infusion daily x 5
Study: NCT00656461
Drug: MKC-1
Normalized name: MKC-1
DrugBank: MKC-1 (DB05608)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg and 100 mg capsules, dosed BID daily on a continuous schedule
Study: NCT00079794
Drug: Iscar
Normalized name: Iscar
DrugBank: Dibenzyl (carbonylbis{2,1-hydrazinediyl[(2S)-4-methyl-1-oxo-1,2-pentanediyl]})biscarbamate (DB03891)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03188614
Drug: Fluid resuscitation
Normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
Study: NCT00249938
Drug: Minute Maid Heart Wise orange juice
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00249938
Drug: Welchol
Normalized name: Welchol
DrugBank: Colesevelam (DB00930)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01681277
Drug: BI 113608 PIB bid
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: powder for oral solution
Study: NCT01681277
Drug: BI 113608 PIB qd
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: powder for oral solution
Study: NCT02858453
Drug: AQX-1125 100 mg
Normalized name: AQX-1125
DrugBank: AQX-1125 (DB13012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic SHIP1 activator
Study: NCT02858453
Drug: AQX-1125 200 mg
Normalized name: AQX-1125
DrugBank: AQX-1125 (DB13012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic SHIP1 activator
Study: NCT01200342
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m\^2 by vein over 3 hours on Day 3 of a 21 day cycle following Genasense.
Study: NCT01200342
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin starting dose in mg (AUC= 6) is administered over 30 minutes IV Piggyback (IVPB). Carboplatin will be dosed after Paclitaxel dose on Day 3 every 3 weeks.~The total dose of Carboplatin is calculated using a formula based upon a participant's glomerular filtration rate (GFR in mL/min) and Carboplatin target area under the concentration (AUC).
Study: NCT00004203
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02434757
Drug: H.P. Acthar Gel
Normalized name: H.P. acthar gel
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acthar 40 U given SC daily for 7 days. Depending on the response and the Investigator,Acthar 40 U will continue Acthar 40 U 2x per week or increase to Acthar 80 U daily for 7 days followed by 2x per week
Study: NCT02385058
Drug: Mebendazole
Normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.
Study: NCT02385058
Drug: Quinfamide
Normalized name: quinfamide
DrugBank: Quinfamide (DB12780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinfamide 200 mg tablet orally once starting on Day 1 and 21.
Study: NCT01971580
Drug: Ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00005991
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00272766
Drug: pegaptanib sodium
Normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04773886
Drug: Mineral trioxide aggregate
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vital Pulpotomy will be done using Mineral trioxide aggregate (MTA) as pulp capping agent
Study: NCT04220398
Drug: Neoadjuvant chemotherapy combined with hormone therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2 IV (every 3 weeks) +Prednisone 5mg BID orally + HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 4-6 cycles
Study: NCT04220398
Drug: Neoadjuvant hormone therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HT (Bicalutamide Tablets, 50mg QD orally; Goserelin, 3.6mg, subcutaneous injection, q28d), 3-6 cycles
Study: NCT02294357
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02294357
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If the patient was receiving steroids at the equivalent of \> 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.
Study: NCT02294357
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: f the patient was receiving prednisone, at the equivalent of \> 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.
Study: NCT02294357
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: If the patient was receiving methylprednisolone at the equivalent of \> 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.
Study: NCT02294357
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: given at same dose and schedule as patient was receiving while being treated with twice weekly carfilzomib at 27 mg/m2
Study: NCT02294357
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: administered PO at 4mg daily on days 1-21 of a 28 day cycle
Study: NCT01516255
Drug: liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
Study: NCT01516255
Drug: moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where a single dose of 400 mg moxifloxacin (tablets) is administered as positive control
Study: NCT04486625
Drug: Aztreonam-Avibactam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500/167 mg ATM/AVI loading infusion, followed by 1500/500 mg ATM/AVI extended loading infusion, then 1500/500 mg ATM/AVI maintenance dose infusion every 6 hours
Study: NCT04486625
Drug: Aztreonam-Avibactam
DrugBank: Aztreonam (DB00355)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 675/225 mg ATM/AVI loading infusion, followed by 675/225 mg ATM/AVI extended loading infusion, then 675/225 mg ATM/AVI maintenance dose infusion every 8 hours
Study: NCT00725270
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg of mifepristone
Study: NCT01551797
Drug: Paracetamol 500 mg
Normalized name: Paracetamol 500 mg oral tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Paracetamol formulation
Study: NCT01551797
Drug: Paracetamol 1000 mg
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol Sustained Release formulation
Study: NCT01551797
Drug: Paracetamol 750 mg
Normalized name: Hydrocodone bitartrate 7.5 mg and paracetamol 750 mg oral tablet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol Sustained Release formulation
Study: NCT01423591
Drug: infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 5 mg/kg. i.v. at week 0, 2, 6, 14 y 22.
Study: NCT01376453
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In addition to radiation and 5-FU, sorafenib will be taken by mouth daily every day until the last day of radiation. The dose of sorafenib will be one of the following: 200 mg every other day, 200 mg daily, 400 mg daily, or 800 mg daily
Study: NCT01376453
Drug: 5-Fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU will be delivered at a dose of 225 mg/m\^2 daily through a catheter in a large vein continuously until the last day of radiation.
Study: NCT00010153
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04415320
Drug: X-396(Ensartinib)
Normalized name: X-396
DrugBank: X-396 (DB13104)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All consented, enrolled, eligible patients receive X-396 capsules, 225mg once daily.
Study: NCT04078295
Drug: E7389-LF
Normalized name: HYDROXYPROPYL CELLULOSE LF
DrugBank: Hydroxypropyl cellulose (DB00840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E7389-LF Intravenous infusion.
Study: NCT04078295
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab Intravenous infusion.
Study: NCT02535039
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anaesthesia in giving 1 mg/kg intravenous methylprednisolone, methylprednisolone (1 mg/kg \* d for application to the third day after surgery
Study: NCT03602300
Drug: Ravidasvir test formulation produced by Doppel
DrugBank: Ravidasvir (DB15652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions.
Study: NCT03602300
Drug: Ravidasvir reference formulation produced by EEPI
DrugBank: Ravidasvir (DB15652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To compare the rate and extent of absorption for RDV when administered as a single 200 mg oral dose of the proposed commercial product (test) produced by Doppel Farmaceutici with the clinical trial product (reference) manufactured by EEPI in healthy volunteers, under fasted conditions.
Study: NCT00667225
Drug: cantharidin's vehicle
DrugBank: Cantharidin (DB12328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cantharidin's vehicle is composed of: Hydroxypropylcellulose, Acetone, and Collodion Flexible. The vehicle will be topically applied to molluscum lesions at each visit. Only two lesions will be treated at the first visit, and up to 20 lesions can be treated at subsequent visits.
Study: NCT00667225
Drug: Cantharidin 0.7%
Normalized name: CANTHARIDIN 0.7% LIQUID,TOP
DrugBank: Cantharidin (DB12328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will receive cantharidin at all visits. At the first visit, up to 2 lesions can have application with cantharidin. All other visits will have up to 20 lesions with application of the cantharidin. During every visit, lesions will be counted and subjects will be assessed for any adverse events.
Study: NCT04425590
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 100 mg tablet once daily
Study: NCT01955187
Drug: TACROLIMUS
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initial dose: 0.05 mg/Kg/day, adjusted to achieve blood trough levels of 5-7 ng/ml) for six months. Starting at the end of month 6, tacrolimus dosage will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
Study: NCT01955187
Drug: RITUXIMAB
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A dose 1 g IV will be given during month 6 (at day 180), before the onset of tacrolimus dose reduction
Study: NCT01955187
Drug: METHYLPREDNISOLONE
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Month 1: 1g IV methylprednisolone daily for three doses (days 1, 2, and 3), Oral methylprednisolone (0.5mg/kg/day) for 27 days (days 4 to 30). Months 3, and 5: Repeat Month 1.
Study: NCT03251729
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
Study: NCT01480063
Drug: Fampridine
Normalized name: FAMPRIDINE
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fampridine administered as prescribed in routine clinical practice. Biogen is not supplying drug for this study.
Study: NCT00618176
Drug: Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP)
Normalized name: lamivudine / nevirapine / zidovudine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (AZT) 300mg bid Didanosine (ddI) 200mg bid (W\>60Kg)125mg bid (W\<60Kg) Nevirapine (NVP) 200mg bid
Study: NCT00618176
Drug: Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP)
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stavudine (d4T) 30mg bid (W\>60Kg)20mg bid (W\<60Kg) Lamivudine (3TC)300mg qd Nevirapine (NVP)200mg bid
Study: NCT00618176
Drug: Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (AZT) 300mg bid Lamivudine (3TC) 300mg qd Nevirapine (NVP) 200mg bid
Study: NCT01986088
Drug: Eletriptan 40 mg
Normalized name: eletriptan 40 MG
DrugBank: Eletriptan (DB00216)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg oral
Study: NCT01986088
Drug: Sumatriptan 50 mg
Normalized name: sumatriptan 50 MG
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg oral
Study: NCT01986088
Drug: Sumatriptan 100 mg
Normalized name: sumatriptan 100 MG
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg oral
Study: NCT02963090
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topotecan at 1.25mg/m2 on days 1 to 5 every 21-days until progression of disease or unacceptable toxicities.~Patients with progression of disease by RECIST 1.1 will be allowed cross over to receive pembrolizumab 200 mg IV every 21-days for up to 1 year until progression of disease or unacceptable toxicities.
Study: NCT02963090
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg IV every 21-days until progression of disease or unacceptable toxicities.
Study: NCT06242769
Drug: Stannous Fluoride Toothpaste (SnF)
Normalized name: stannous fluoride Toothpaste
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: test
Study: NCT06242769
Drug: Colgate Fluoride Toothpaste (CDC)
Normalized name: sodium fluoride Mouthwash [Colgate]
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: negative control
Study: NCT00463671
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02179177
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug is taken by mouth twice a day for 6 months
Study: NCT00390520
Drug: Vildagliptin
Normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT03843853
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pemetrexed 500 mg/m2 d1
Study: NCT03843853
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1 (20mg、25mg), capsule, 40\~60mg, Bid,p.o, d1\~14
Study: NCT03843853
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 7.5 mg/kg d1